Precision medicine for metastatic renal cell carcinoma11Disclosures: Guru Sonpavde, MD: Research support from Novartis, Pfizer, and speaker or advisory board for Novartis, Pfizer, and GSK. Toni K. Choueiri, MD: Research support from Pfizer. Advisory board: Pfizer, Novartis, Aveo, GSK, Bayer/Onyx, and Genentech. No speakers bureau.-Reference-Cited by-同舟云学术

Precision medicine for metastatic renal cell carcinoma11Disclosures: Guru Sonpavde, MD: Research support from Novartis, Pfizer, and speaker or advisory board for Novartis, Pfizer, and GSK. Toni K. Choueiri, MD: Research support from Pfizer. Advisory board: Pfizer, Novartis, Aveo, GSK, Bayer/Onyx, and Genentech. No speakers bureau.

Published:2014-01 Issue:1 Volume:32 Page:5-15
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Sonpavde Guru,Choueiri Toni K.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference112 articles.

1. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma;McDermott;J Clin Oncol,2005

2. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

3. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med,2007

4. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma;Motzer;Clin Genitourin Cancer,2009

5. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma;Feldman;J Clin Oncol,2009

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Setting Research Priorities for Kidney Cancer;European Urology;2017-12

2. The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians;Canadian Urological Association Journal;2017-11-01

3. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review;Current Drug Targets;2017-07-10

4. Treatment Overview;Renal Cell Carcinoma;2017

5. Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine;Spine;2016-10-15